Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Kroken, Rune A ^a   Johnsen, Erik ^a   Ruud, Torleif ^c,d   Wentzel Larsen, Tore ^a   Jørgensen, Hugo A ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d SINTEF   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIXYRAZINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; HALDOL DEPOT; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PERPHENAZINE DECANOATE; PROCHLORPERAZINE MALEATE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TRILAFON DEPOT; UNCLASSIFIED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; COMORBIDITY; DELUSION; EMERGENCY WARD; FEMALE; HALLUCINATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; NORWAY; OUTPATIENT; PERSONALITY DISORDER; POLYPHARMACY; RECURRENCE RISK; SCHIZOPHRENIA; CLINICAL PRACTICE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; MIDDLE AGED; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RISK FACTOR; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CLOZAPINE; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 67649695935     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-24     Document Type: Article

References (39)

1. Moore TA Buchanan RW Buckley PF Chiles JA Conley RR Crismon ML Essock SM Finnerty M Marder SR Miller DD McEvoy JP Robinson DG Schooler NR Shon SP Stroup TS Miller AL The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update J Clin Psychiatry 2007, 68:1751-1762 18052569
2. Lehman AF Kreyenbuhl J Buchanan RW Dickerson FB Dixon LB Goldberg R Green-Paden LD Tenhula WN Boerescu D Tek C Sandson N Steinwachs DM The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003 Schizophr Bull 2004, 30:193-217. 15279040
3. National Institute for Clinical Excellence Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care National Institute for Clinical Excellence. London 2002.
4. Lehman AF Lieberman JA Dixon LB McGlashan TH Miller AL Perkins DO Kreyenbuhl J Practice guideline for the treatment of patients with schizophrenia, second edition Am J Psychiatry 2004, 161:1-56. 10.1176/ appi.ajp.161.1.1 15000267
5. Gaebel W Weinmann S Sartorius N Rutz W McIntyre JS Schizophrenia practice guidelines: International survey and comparison Br J Psychiatry 2005, 187:248-255. 10.1192/bjp.187.3.248 16135862
6. Tandon R Belmaker RH Gattaz WF Lopez-Ibor JJ Jr Okasha A Singh B Stein DJ Olie J-P Fleischhacker WW Moeller H-J World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia Schizophr Res 2008, 100:20-38. 10.1016/j.schres.2007.11.033 18243663
7. Leucht S Psychiatric treatment guidelines: Doctors' non-compliance or insufficient evidence? Acta Psychiatr Scand 2007, 115:417-419. 10.1111/ j.1600-0447.2007.01030.x 17498152
8. Johnsen E Svingen GF Jorgensen HA Practice regarding antipsychotic therapy: A cross-sectional survey in two Norwegian hospitals Nord J Psychiatry 2004, 58:313-317. 10.1080/08039480410005837 15370781
9. Barbui C Nose M Mazzi MA Thornicroft G Schene A Becker T Bindman J Leese M Helm H Koeter M Weinmann S Tansella M Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries Int Clin Psychopharmacol 2006, 21:355-362. 10.1097/ 01.yic.0000224785.68040.43 17012982
10. Bitter I Chou JC Ungvari GS Tang WK Xiang Z Iwanami A Gaszner P Prescribing for inpatients with schizophrenia: An international multi-center comparative study Pharmacopsychiatry 2003, 36:143-149. 10.1055/s-2003-41199 12905100
11. Lambert M Conus P Eide P Mass R Karow A Moritz S Golks D Naber D Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence Eur Psychiatry 2004, 19:415-422. 10.1016/j.eurpsy.2004.06.031 15504648
12. Tunis SL Faries DE Nyhuis AW Kinon BJ Ascher-Svanum H Aquila R Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, 1-year trial Value Health 2006, 9:77-89. 10.1111/j.1524-4733.2006.00083.x 16626411
13. Ruud T Gråwe RW Hatling T Acute Psychiatric Treatment in Norway - results from a multicenter study. (In Norwegian) Sintef Helse, Trondheim, Norway 2006.
14. Karterud S Pedersen G Loevdahl H Friis S Global Assessment of Functioning - Split Version (S-GAF): Background and Scoring Manual Ullevål University Hospital, Department of Psychiatry. Oslo, Norway 1998.
15. American Psychiatric Assosiation Diagnostic and Statistical Manual of Mental Disorders American Psychiatric Publishing, Washington DC 4 1994.
16. Wing JK Beevor AS Curtis RH Park SB Hadden S Burns A Health of the Nation Outcome Scales (HoNOS). Research and development Br J Psychiatry 1998, 172:11-18. 10.1192/bjp.172.1.11 9534825
17. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders, Clinical Description and Diagnostic Guidelines World Health Organization, Geneva 1992.
18. Bazire S Psychotropic Drug Directory Fivepin Limited, Salisbury 2005.
19. Davis JM Dose equivalence of the antipsychotic drugs J Psychiatr Res 1974, 11:65-69. 10.1016/0022-3956(74)90071-5 4156792
20. Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003, 64:663-667. 12823080
21. Kane JM Aguglia E Altamura AC Ayuso Gutierrez JL Brunello N Fleischhacker WW Gaebel W Gerlach J Guelfi J-D Kissling W Lapierre YD Lindstrøm E Mendlewicz J Racagni G Carulla LS Schooler NR Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy Eur Neuropsychopharmacol 1998, 8:55-66. 10.1016/S0924-977X(97)00045-X 9452941
22. WHO Collaborating Centre for Drug Statistics Methodology ATC classification index with DDDs 2008. Oslo, Norway 2008.
23. Royal Pharmaceutical Society of Great Britain British National Formulary 2008 RPS Publishing, London 2008.
24. Bai YM Ting CT Chen JY Chang WH Wu B Hung CH Lin WK Equivalent switching dose from oral risperidone to risperidone long-acting injection: A 48-week randomized, prospective, single-blind pharmacokinetic study J Clin Psychiatry 2007, 68:1218-1225. 17854246
25. Danish National Board of Health Use of antipsychotics in patients aged 18-64 years with schizophrenia, mania or bipolar affective disorder. (In Danish) Copenhagen, Denmark 2006.
26. Ballerini A Boccalon RM Boncompagni G Casacchia M Margari F Minervini L Righi R Russo F Salteri A Frediani S Rossi A Scatigna M Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: The PERSEO (psychiatric emergency study and epidemiology) survey Ann Gen Psychiatry 2007, 6:29. 2186309 17983468 10.1186/1744-859X-6-29
27. Procyshyn RM Kennedy NB Tse G Thompson B Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution Can J Psychiatry 2001, 46:334-339. 11387789
28. Edlinger M Hausmann A Kemmler G Kurz M Kurzthaler I Walch T Walpoth M Fleischhacker WW Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period Schizophr Res 2005, 77:25-34. 10.1016/j.schres.2005.01.015 16005382
29. Kreyenbuhl J Valenstein M McCarthy JF Ganoczy D Blow FC Long-term combination antipsychotic treatment in VA patients with schizophrenia Schizophr Res 2006, 84:90-99. 10.1016/j.schres.2006.02.023 16631354
30. Weiden PJ Casey DE "Polypharmacy:" Combining Antipsychotic Medications in the Treatment of Schizophrenia Jrnl Prac Psych and Behav Hlth 1999, 5:229-233.
31. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RSE Davis SM Davis CE Lebowitz BD Severe J Hsiao JK Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005, 12:1209-23. 10.1056/NEJMoa051688
32. Johnsen E Jorgensen HA Effectiveness of second generation antipsychotics: A systematic review of randomized trials BMC Psychiatry 2008, 8:31. 2386457 18439263 10.1186/1471-244X-8-31
33. Correll CU Leucht S Kane JM Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies Am J Psychiatry 2004, 161:414-425. 10.1176/appi.ajp.161.3.414 14992963
34. Kreyenbuhl JA Valenstein M McCarthy JF Ganoczy D Blow FC Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns Psychiatr Serv 2007, 58:489-495. 10.1176/appi.ps.58.4.489 17412850
35. Ray WA Chung CP Murray KT Hall K Stein CM Atypical antipsychotic drugs and the risk of sudden cardiac death N Engl J Med 2009, 360:225-235. 10.1056/NEJMoa0806994 19144938
36. Tauscher J Kapur S Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies CNS Drugs 2001, 15:671-678. 10.2165/00023210-200115090-00001 11580306
37. Rijcken CA Monster TB Brouwers JR de Jong-van den Berg LT Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses? J Clin Psychopharmacol 2003, 23:657-659. 10.1097/ 01.jcp.0000096247.29231.3a 14624195
38. Hamann J Langer B Leucht S Busch R Kissling W Medical decision making in antipsychotic drug choice for schizophrenia Am J Psychiatry 2004, 161:1301-1304. 10.1176/appi.ajp.161.7.1301 15229068
39. Weinmann S Janssen B Gaebel W Guideline adherence in medication management of psychotic disorders: An observational multisite hospital study Acta Psychiatr Scand 2005, 112:18-25. 10.1111/ j.1600-0447.2005.00547.x 15952941